The notion that higher drug levels may correlate with better efficacy is further supported by the finding that hypertension, thought to be an independent pharmacodynamic marker of VEGFR inhibition, correlated with response in a retrospective study of patients treated with first or second-line sunitinib [4,5]. Here, KDR is linked to Hypertension.